<DOC>
	<DOCNO>NCT01388569</DOCNO>
	<brief_summary>RATIONALE : Studying sample blood patient treat sargramostim laboratory may help doctor learn effect sargramostim cell . It may also help doctor understand patient respond treatment . PURPOSE : This research trial study biomarkers blood sample patient stage IV melanoma previously treat sargramostim .</brief_summary>
	<brief_title>Biomarkers Blood Samples From Patients With Stage IV Melanoma Previously Treated With Sargramostim</brief_title>
	<detailed_description>OBJECTIVES : Primary - To correlate circulate myeloid-derived suppressor cell ( MDSC ) Treg frequencies clinical outcome . Secondary - To correlate circulate anti-sargramostim ( GM-CSF ) antibody level clinical outcome . OUTLINE : Archived peripheral blood mononuclear cell serum sample analyze circulate myeloid-derived suppressor cell , Treg ( CD3+/CD4+/CD25hi/FOXP3+ ) frequency , anti-sargramostim ( anti-GM-CSF ) antibody level flow cytometry anti-GM-CSF neutralizing antibody assay .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosed melanoma Stage IV disease HLAA2^+ A2^+ Received sargramostim clinical trial ECOG4697 Specimens collect baseline either day 43 day 85 ( base consistent availability ) longterm survivor patient poor survival PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>stage IV melanoma</keyword>
</DOC>